EGF and urinary bladder carcinoma: FGFR mutations are less common in canine bladder cancer, and agents targeting FGFR have not been tested in dogs. Targeted therapies tested in dogs include an EGF-toxin conjugate, and folate targeted therapies (78, 121, 122)